Home » Merck, Codexis Win Presidential Green Chemistry Award for Novel Catalysis
Merck, Codexis Win Presidential Green Chemistry Award for Novel Catalysis
PharmaManufacturing.com
06/22/2010
"Merck has a longstanding commitment to environmental sustainability," said Richard Tillyer, Ph.D, head of Drug Discovery and Preclinical Sciences, Merck Research Laboratories. "This award and the recent publication underscore the strength of the innovative science and the productive collaboration with our colleagues at Codexis."
The publication in Science outlines how Merck and Codexis collaborated to create a custom enzyme, or biocatalyst, that can allow for commercial-scale manufacturing of sitagliptin. No natural enzyme able to produce this compound was found. Enzymes are biodegradable, renewable and are generally believed to provide a more sustainable means of chemical synthesis than many currently employed methods used for the manufacture of pharmaceuticals. Evidence suggests that the new process may offer a 10-13 percent overall increase in yield of sitagliptin over the current process and a significant reduction in waste byproducts.
"Codexis is honored to receive one of the U.S. government's highest awards for environmental protection with Merck," said Alan Shaw, Ph.D., Codexis President and CEO. "Our proven technology platform is in use around the world, enabling creation of cleaner, more efficient pharmaceutical manufacturing processes. We are committed, with our colleagues at Merck, to leveraging the power of green chemistry for a sustainable environment."
About Presidential Green Chemistry Challenge Awards Program
The Presidential Green Chemistry Challenge Awards are presented annually by the Environmental Protection Agency to recognize new technologies that help prevent pollution by reducing or eliminating hazardous waste in industrial production. It provides recognition of outstanding chemical technologies that incorporate the principles of green chemistry into chemical design, manufacture, and use, and that have been or can be utilized by industry in achieving their pollution prevention goals. The award was launched in 1995 in partnership with the chemical industry, the American Chemical Society, the National Academies and other stakeholders. Both Merck and Codexis won awards individually in 2006.
More News:
-
06/18/2013
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
-
06/18/2013
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
-
06/18/2013
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
-
06/18/2013
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
-
06/17/2013
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
-
06/14/2013
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
-
06/14/2013
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
-
06/13/2013
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
-
06/13/2013
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
-
06/13/2013
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »
Get Connected Now!
- Featured White Papers

Print page